M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

Not Applicable

Completed

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Procedure: Colposcopic biopsy
Procedure: Light-Scattering Spectroscopy

First Posted Date: 2004-06-11

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1070

Registration Number: NCT00084903

Locations: 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Phase 2

Completed

Conditions: Metastatic Cancer
Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Imatinib mesylate

First Posted Date: 2004-06-11

Last Posted Date: 2012-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00084825

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Biological: PEG-interferon alfa-2b

First Posted Date: 2004-06-11

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00085384

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Amoxicillin
Drug: Bismuth Subsalicylate
Drug: Clarithromycin
Drug: Metronidazole Hydrochloride
Drug: Omeprazole
Drug: Tetracycline Hydrochloride

First Posted Date: 2004-06-10

Last Posted Date: 2018-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00002682

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States

SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver

Phase 1

Withdrawn

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: SCH 66336
Procedure: conventional surgery

First Posted Date: 2004-06-04

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00005030

Use of Nesiritide in the Management of Acute Diastolic Heart Failure

Phase 4

Terminated

Conditions: Congestive Heart Failure
Heart Failure
Cardiovascular Disease
Diastolic Heart Failure
Heart Disease
Acute Heart Failure

Interventions: Drug: Nesiritide

First Posted Date: 2004-06-03

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00083772

Fenretinide in Treating Patients With Cervical Neoplasia

Phase 3

Completed

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Other: Placebo
Drug: Fenretinide

First Posted Date: 2004-05-27

Last Posted Date: 2018-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00003075

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Phase 2

Completed

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Other: Placebo
Drug: Eflornithine

First Posted Date: 2004-05-26

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT00006079

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Bone Marrow Transplantation in Treating Patients With Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Recombinant Interferon Alfa
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Mesna
Procedure: Bone Marrow Transplantation
Radiation: Radiation Therapy

First Posted Date: 2004-05-26

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT00002829

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine phosphate sodium
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Paclitaxel
Drug: Ketoconazole
Drug: Vinblastine

First Posted Date: 2004-05-24

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT00003084

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy